<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>19</Volume>
				<Issue>1</Issue>
				<PubDate PubStatus="epublish">
					<Year>2018</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>39</FirstPage>
			<LastPage>43</LastPage>
			<ELocationID EIdType="pii">55062</ELocationID>
			
<ELocationID EIdType="doi">10.22034/APJCP.2018.19.1.39</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mozaffar </FirstName>
					<LastName>Aznab</LastName>
<Affiliation>Medical Hematologist-Oncologist, School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran.</Affiliation>
<Identifier Source="ORCID">0000-0002-1498-5205</Identifier>

</Author>
<Author>
					<FirstName>Sayed Mojtaba </FirstName>
					<LastName>Akhmadi</LastName>
<Affiliation>Department of Clinical Psychology, School of Medicine, Kermanshah University of Medical
Science, Kermanshah, Iran.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2017</Year>
					<Month>05</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract> &lt;br /&gt; &lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Objective: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;Despite the development of two significant classifications for recurrence risk evaluation among patients &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;engaged with gastrointestinal stromal tumor and corresponding treatment criteria, recurrence happens in a number &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;of the patients who were once classified as ineligible for treatment and hence removed from treatment program. As &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;such, the aim of the present study is to increase the number of patients recognized as eligible for treatment, so as to further reduce recurrence rate of this disease. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;A total of 26 patients from Ilam, Kermanshah, Lorestan, Kurdistan, and some parts of Hamedan, entered this study from 2006 until 2016. The western provinces &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;included have similar socioeconomical conditions. Inclusion criteria were operable tumors confirmed radiologically with a gross size larger than 3 centimeters regardless of the mitosis rate in microscopic power fields, tumor location, or &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;presence of peritoneal involvement during the surgery. Imatinib capsules were administered daily at 400 mg for 3 years. The patients were followed up every 3 months by radiology, ultrasonography, biochemical assessment, and clinical examination. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Results and Conclusions: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;The overall survival after 10-years follow up was 100%, while 5-year survival without relapse was 95%. Mean overall survival was 106 months, and only one patient who had limited peritoneal &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;involvement experienced relapse and he is still alive after 2 years. The drug was well tolerated and no significant side &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;effects were observed. &lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">GIST</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">imatinib</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Target Therapy</Param>
			</Object>
		</ObjectList>
</Article>
</ArticleSet>
